Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative...

Area of Science:

• Oncology
• Surgical Oncology
• Clinical Trials

Background:

• Sentinel lymph node (SLN) surgery aims to reduce side effects compared to axillary lymph node dissection (ALND) while maintaining equivalent outcomes.
• The NSABP B-32 trial investigated the efficacy of SLN resection alone versus SLN resection plus ALND in breast cancer patients.

Purpose of the Study:

• To determine if SLN resection in breast cancer patients achieves survival and regional control comparable to ALND.
• To assess if SLN surgery alone results in fewer side effects than ALND.

Main Methods:

• A randomized phase 3 trial (NSABP B-32) involving 5611 women across 80 centers in Canada and the USA.
• Patients were assigned to SLN resection plus ALND or SLN resection alone (ALND only if SLNs were positive).
• Primary endpoint was overall survival, analyzed on an intention-to-treat basis using Kaplan-Meier estimates and log-rank tests.

Main Results:

• No statistically significant difference in overall survival (8-year estimates: 91.8% vs 90.3%) or disease-free survival (8-year estimates: 82.4% vs 81.5%) between the groups.
• Regional-node recurrences were similar (8 in group 1 vs 14 in group 2).
• Allergic reactions to blue dye were the most common adverse events.

Conclusions:

• SLN surgery alone is a safe and effective alternative to ALND for breast cancer patients with clinically negative lymph nodes.
• The study demonstrates statistical equivalence in survival, disease-free survival, and regional control.
• SLN resection alone is an appropriate therapeutic option when sentinel nodes are negative.